(QDEL) Quidel - Ratings and Ratios

QuidelOrtho Corporation is a leading provider of diagnostic testing solutions, operating through four distinct business units: Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics. The companys product portfolio includes a wide range of diagnostic instruments and tests that cater to various healthcare needs, from clinical chemistry laboratory testing to molecular diagnostics. QuidelOrthos products are designed to provide accurate and rapid results, enabling healthcare professionals to make informed decisions and improve patient outcomes.

The companys business units are strategically positioned to address different segments of the healthcare industry. The Labs business unit offers a broad range of laboratory instruments and tests, while the Transfusion Medicine unit focuses on ensuring patient-donor compatibility in blood transfusions. The Point of Care unit provides rapid testing solutions for various healthcare settings, and the Molecular Diagnostics unit offers advanced molecular testing solutions for infectious disease diagnostics.

QuidelOrthos products are sold through a combination of direct sales and distribution channels, allowing the company to reach a wide range of customers, including hospitals, clinical laboratories, and physician offices. The companys global presence spans North America, Europe, the Middle East, Africa, China, and other international markets.

Analyzing the technical data, we observe that QDELs last price is $29.88, with a 20-day SMA of $30.89 and a 50-day SMA of $29.71, indicating a potential short-term downtrend. The 200-day SMA of $38.48 suggests a longer-term downtrend. The ATR of 1.87 represents a 6.25% daily price volatility. Considering the fundamental data, QDELs market capitalization is approximately $2.09 billion, with a forward P/E ratio of 12.38, indicating a relatively reasonable valuation. However, the negative RoE of -10.82% raises concerns about the companys profitability.

Based on the technical and fundamental analysis, our forecast suggests that QDEL may experience a short-term price correction, potentially testing the 52-week low of $24.46. However, if the company can demonstrate improved profitability and revenue growth, the stock may rebound towards the 200-day SMA of $38.48. Investors should closely monitor QDELs future earnings reports and industry trends to reassess the companys prospects.